Navigation Links
Amedica® Receives Patent for Knee Prosthesis With Monoblock Silicon Nitride Ceramic Tibial Component
Date:8/31/2010

SALT LAKE CITY, Aug. 31 /PRNewswire/ -- Amedica Corporation, a spinal and orthopaedic implant and instrument company focused on unique silicon nitride (SiN) ceramic technologies, announced today that it has been granted United States Patent No. 7,776,085 B2, covering an improved knee implant prosthesis that features a monoblock ceramic tibial component for articulation with natural or prosthetic (resurfaced) femoral surfaces.  This is an important addition to Amedica's substantial and growing patent portfolio concerning silicon nitride hip and knee implants.

The tibial component is created from a silicon nitride monoblock adapted for fixation relative to a patient's tibial bone. Alternately, it can be affixed by a ceramic bearing insert component carried by a tibial baseplate member that is adapted for fixation relative to the tibial bone. In either form, the monoblock silicon nitride tibial component includes one or more upwardly concave articulation surface that promotes movable bearing engagement with a generally convex or condylar-shaped femoral articulation surface.

According to Ben Shappley, Chief Executive Officer, President and Director of Amedica, the monoblock silicon nitride technology with an innovative bone-contacting Bioactive™ surface provides implants with remarkable wear characteristics and extended service life. In the long term, the technology helps surgeons achieve more successful outcomes in restoring patient function and allows individuals to return to productive and pain-free lives.

"Improvements in knee prostheses using monoblock silicon nitride with bio-ingrowth technology in the tibial component eliminate conventional polymer-based bearing inserts and the related, undesirable wear debris problems and revisions associated with the older technologies used in current implants," said Shappley. "Our unique technology allows us to combine our high-strength silicon nitride with an ultra-low wear, surface-bearing technology that is designed for secure, lifetime fixation.  This gives surgeons flexibility in design choices and the ability to improve anatomic fit and function for positive, lasting results and significant outcome improvement."

Amedica, a full-line manufacturer and supplier of silicon nitride technologies that are used in spinal implant applications, has developed unique SiN materials having disruptive characteristics for spinal, hip and knee implant applications. The material is remarkably fracture resistant, and its articulating surfaces do not produce the wear debris that is linked to osteolysis-related re-operations. Additionally, the Bioactive implants provide a hydrophilic surface and a conductive cancellous structure that enhances bone ingrowth and attachment.

The company recently entered into a Joint Venture Agreement with Orthopaedic Synergies Inc., a global reconstructive hip and knee concern known for its innovative and new implant technologies, expanding its reach into a more widespread orthopaedic marketplace.

"This latest patent for expanded use of our monoblock silicon nitride technology further marks a notable milestone in orthopaedic implants and other related applications," Shappley notes. "It also further secures Amedica's future competitive position in the reconstructive implant segment, which is one of the largest and rapidly-growing segments in the industry."

About Amedica:

Amedica Corporation is ISO 13485 certified and its products are FDA cleared and CE approved.  Amedica Corporation is an emerging orthopaedic implant company focused on using its silicon nitride ceramic technologies to develop and commercialize a broad range of innovative, unique spine and total joint implants for the growing orthopaedic device market.  It has brought to market various spinal implant products, while products under development include reconstructive hip and knee implants that represent a new standard of care in total joint implants based on superior performance, safety and efficacy.


'/>"/>
SOURCE Amedica Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amedica® Receives Patent for Hip Implant Using Monoblock Ceramic Technology
2. Bionovo Receives Positive Guidance from FDA on Menerba®
3. BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease
4. Bend Research Receives Patent for Preparing Spray-Dried Drug Dispersions Using Pressure Nozzles
5. Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure
6. Endologix Receives CE Mark Approval for Expanded Line of Powerlink Products and PowerFit Aortic Extensions
7. KemPharm, Inc. Receives Notice of Issuance from USPTO on Second Patent Protecting Companys ADHD Prodrug Technology
8. Pentasa(R) - Shire Receives Ruling From FDA on Citizens Petition
9. +PLUSPAK (polymer bottle) Packaging Receives GEs Distinguished ecomagination(SM) Approval
10. PROLOR Biotech Receives FDA Clearance for a Phase II Trial of Its Long-Acting Human Growth Hormone in the U.S.
11. Celsion Receives Fast Track Designation for ThermoDox® Development Program to Treat Primary Liver Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
(Date:5/18/2017)... -- Bayer announced today that the latest research from across ... 53 rd Annual Meeting of the American Society ... Chicago . The ... and thyroid cancers, as well as lymphomas, and includes ... of copanlisib in patients with relapsed or refractory follicular ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
Breaking Medicine Technology:
(Date:5/24/2017)... , ... May 24, 2017 , ... ... of ExtraHop to its solutions portfolio. ExtraHop delivers an analytics-first approach, layered with ... every IT system, from the datacenter to the cloud to the edge. Through ...
(Date:5/24/2017)... ... 24, 2017 , ... The CFOs included on this list ... in the nation and help their organizations navigate the challenges in healthcare today. ... in developing successful hospital and health system strategy. , Becker's Hospital Review has ...
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand International (MDLand), a ... today that its iClinic V12.2 solution has achieved approval from National Center for ... PCMH 2017 standards which emphasize team-based care with a significant focus on the ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge, MA, May ... since 2009, according to a Workers Compensation Research Institute (WCRI) study, a contrast ... North Carolina System: CompScope™ Benchmarks, 17th Edition looks at indemnity and medical ...
(Date:5/23/2017)... ... 2017 , ... London, May 23, 2017: Walter Schindler, the Founder and Managing ... Guest Speaker and Contributor to a weeklong series of classes, meetings, field trips and ... , Walter Schindler and SAIL Capital have received an increasing number ...
Breaking Medicine News(10 mins):